Zephyr AI works on real-world clinical data for drug development and diagnostics, turning fragmented multi-modal sources into findings that slot into existing R&D and clinical workflows across discovery, validation and deployment.
Two claims carry the weight. Interpretable models matter because a target hypothesis a biologist cannot interrogate is not actionable however good the prediction, and regulators will ask the same question later. Requiring no new assays matters commercially: a platform that needs fresh sample collection is a multi-year programme, while one that works on data already generated can produce something this quarter.
It sells to biopharma and diagnostics companies with no pricing published and only a contact form. Real-world data carries the biases of who received care and where, which propagate into any model built on it; interpretability is a spectrum rather than a property; and precision medicine findings need prospective validation before they change any clinical decision.
